TEVA241220C16500
- 4.70
- 0.000.00%
Teva Pharmaceutical Industries Newsroom
UBS Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Raises Target Price to $28
Teva Pharmaceutical Industries Options Spot-On: On December 18th, 95,900 Contracts Were Traded, With 952.86K Open Interest
Jim Cramer on Teva Pharmaceutical Industries (TEVA): A Game-Changer for Intractable Disease Treatments?
Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases
Teva Pharmaceutical Stock Positioned for Even Better Performance in 2025, UBS Says
Express News | U.S. Supreme Court Agrees To Hear South Carolina's Bid To End Public Funding Of Abortion Provider Planned Parenthood
Teva Pharmaceutical Indus Analyst Ratings
FDA Approves Celltrion's Biosimilar of J&J's Stelara
Express News | Teva : BofA Global Research Raises Price Objective to $25 From $23
Daily short sale tracking: NVIDIA's short volume increased by 5 million, with a short sale ratio of 10%
SNY, TEVA Stocks Jump on Encouraging Data From IBD Drug Study
Barclays Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Raises Target Price to $28
Strength Seen in Teva Pharmaceutical Industries (TEVA): Can Its 26.5% Jump Turn Into More Strength?
Teva Pharmaceutical Industries Limited's (NYSE:TEVA) Price Is Right But Growth Is Lacking After Shares Rocket 27%
Why These Two Pharma Stocks Are Surging
J.P. Morgan Maintains Teva Pharmaceutical Industries(TEVA.US) With Hold Rating
Nukkleus, Micron, Teva Pharmaceutical, Quantum Computing, Tesla: Why These 5 Stocks Are On Investors' Radars Today
Teva Pharmaceutical (TEVA) Gets a Hold From J.P. Morgan
Top Gap Ups and Downs on Tuesday: TEVA, NET, SAN and More
Unusual Options Activity: WLK, VOD and Others Attract Market Bets, WLK V/OI Ratio Reaches 199.2